CinPhloro Pharma, A CinRx Portfolio Company, Dosed First Participant in Phase 2 enviva Study of CIN-103 for IBS-D
CinPhloro Pharma Dosed First Participant in Phase 2 enviva Study of CIN-103 for IBS-D.
CinFina Pharma, a CinRx Portfolio Company, Introduces Scientific Advisory Board with Deep Metabolic Expertise
CinFina Pharma, a CinRx Portfolio Company, Introduces Scientific Advisory Board with Deep Metabolic Expertise.
CinRx Portfolio Company CinDome Pharma Presents Encouraging Data on Deudomperidone (CIN-102) at 2023 Digestive Disease Week® Conference
CinDome Pharma, a CinRx portfolio company, presented a poster at the 2023 Digestive Disease Week (DDW) Conference.
